Hawaii Biotech names partner for dengue preclinical work
Hawaii Biotech Inc., a company developing a dengue vaccine, said it will partner with Advanced BioScience Laboratories Inc. for preclinical development of the vaccine.
Hawaii Biotech is planning to begin Phase 1 human clinical study of its tetravalent dengue vaccine later this year. Under a contract from the National Institute of Allergy and Infectious Diseases, Advanced BioScience will oversee manufacturing, assembling and testing of supplies.
Hawaii Biotech also is developing a West Nile vaccine and recently completed a Phase 1 clinical trial with it in humans.